Drug class

Antiplatelet and Antithrombotic Drugs (Selected Group 2)

The phrase "Antiplatelet and Antithrombotic Drugs (Selected Group 2)" does not represent a standard, recognized clinical or pharmacological therapeutic class in official medical compendia, FDA Established Pharmacologic Class listings, or major clinical guidelines. Read more about Antiplatelet and Antithrombotic Drugs (Selected Group 2)

104 drugs in this class 73 manufacturers

Advertisement

Drugs in Antiplatelet and Antithrombotic Drugs (Selected Group 2)

Showing 19–27 of 104 drugs

PRASUGREL HCL

ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW · MYOCARDIAL REINFARCTION PREVENTION ·+1
ASCEND LABORATO

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR · ACUTE CORONARY SYNDROME ·+1
ACCORD HEALTHCA

CILOSTAZOL

INTERMITTENT CLAUDICATION AGENTS · INTERMITTENT CLAUDICATION
SLATE RUN PHARM

KENGREAL (cangrelor tetrasodium)

ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW · PERCUTANEOUS CORONARY INTERVENTION ADJUNCT FOR THROMBOSIS PREVENTION
CHIESI USA, INC

WARFARIN SODIUM

ORAL ANTICOAGULANTS · MYOCARDIAL REINFARCTION PREVENTION ·+12
RISING PHARM

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR · ACUTE CORONARY SYNDROME ·+1
SAGENT PHARMACE

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR · ACUTE CORONARY SYNDROME ·+1
MYLAN INSTITUTI
Filter & compare in the drug finder → Opens the drug finder with Antiplatelet and Antithrombotic Drugs (Selected Group 2) preselected. Add indication or manufacturer filters there.

About Antiplatelet and Antithrombotic Drugs (Selected Group 2).

The phrase "Antiplatelet and Antithrombotic Drugs (Selected Group 2)" does not represent a standard, recognized clinical or pharmacological therapeutic class in official medical compendia, FDA Established Pharmacologic Class listings, or major clinical guidelines.

Instead, it reflects an administrative, institutional, or formulary-specific grouping rather than an established physiological classification.

Broadly, antithrombotic and antiplatelet agents prevent pathologic vascular thrombosis by inhibiting platelet activation, aggregation, or components of the coagulation cascade.

Clinically, these agents are utilized to prevent and manage thromboembolic conditions, including acute coronary syndromes, ischemic stroke, transient ischemic attacks, and deep vein thrombosis.